Last reviewed: April 25, 2026 — Reviewed by: ZYNDIO Editorial Team

TRT Routes Compared: Injectable, Oral, and Transdermal

Testosterone replacement therapy (TRT) is FDA-approved for men with diagnosed hypogonadism — a clinical syndrome with documented low testosterone plus consistent symptoms. The medication is delivered through several routes, each with distinct pharmacokinetics, side effect profiles, and pragmatic considerations. This article walks through the major routes and the trade-offs between them.

Diagnostic prerequisite

Before discussing route, the diagnostic step matters. The Endocrine Society guidelines specify two morning total testosterone measurements (with at least one below the lower reference limit) plus consistent clinical symptoms (Endocrine Society 2018 Guidelines). Testosterone therapy started without this diagnostic foundation creates clinical and regulatory problems.

Injectable routes

Testosterone cypionate (intramuscular). The classical TRT preparation in the U.S. Self-administered or clinic-administered, typically 100-200 mg every 7-14 days. Pharmacokinetics produce a peak shortly after injection and a trough at the end of the cycle. Splitting into smaller, more frequent injections (50-75 mg twice weekly) reduces peak-trough variability and is now widely used.

Testosterone enanthate (intramuscular). Similar pharmacokinetics to cypionate. The two are interchangeable in most clinical contexts. Less commonly prescribed in the U.S.

Testosterone undecanoate (intramuscular, long-acting). FDA-approved as Aveed in the U.S. Administered every 10-14 weeks after initial loading. Requires in-office administration with 30-minute observation due to a rare risk of pulmonary oil microembolism.

Subcutaneous testosterone cypionate. Off-label route gaining clinical traction. Smaller doses (typically the same molecule and concentration, injected with an insulin needle) administered weekly or twice-weekly. Comparable serum levels to IM with reportedly less injection-site discomfort.

Pros of injectable TRT:

  • Most evidence base.
  • Cost-effective (generic cypionate is inexpensive).
  • Reliable serum levels with appropriate dosing schedule.
  • No daily compliance burden.

Cons of injectable TRT:

  • Self-injection or clinic visits required.
  • Peak-trough variability (mitigated by frequent dosing).
  • Some patients dislike injections.

Transdermal routes

Testosterone gel (Androgel, Testim, Fortesta, Vogelxo). Daily application to the upper arms, shoulders, or abdomen. Steady-state levels generally established after 7-14 days.

Testosterone patch (Androderm). Daily nighttime patch, typically applied to the back, abdomen, thighs, or upper arms.

Testosterone solution (Axiron). Daily application to the underarms.

Pros of transdermal:

  • No injections.
  • Steady-state pharmacokinetics avoid peak-trough swings.
  • Dose adjustment easy.

Cons of transdermal:

  • Daily application required (adherence).
  • Risk of secondary transfer to women or children through skin contact — particularly important in households with young children. Site coverage and waiting periods are required per labeling.
  • Some patients have variable absorption based on skin properties.
  • Generally more expensive than injectable.

Oral routes

Testosterone undecanoate (Jatenzo, Tlando, Kyzatrex). FDA-approved oral testosterone preparations in lipid-based capsules. Twice-daily dosing. The lipid-based formulation bypasses first-pass hepatic metabolism, making oral testosterone clinically viable for the first time in the U.S.

Methyltestosterone. An older oral testosterone with significant hepatotoxicity concerns and largely abandoned for routine TRT.

Pros of oral:

  • No injection, no transdermal mess.
  • Discreet.
  • Daily routine integration.

Cons of oral:

  • Twice-daily dosing.
  • Must be taken with food (lipid absorption requirement).
  • More expensive than generic injectable.
  • Newer formulations with shorter clinical track record.
  • Modest blood pressure increase reported with newer oral preparations.

Pellets

Implantable testosterone pellets (Testopel) are surgically inserted subcutaneously every 3-6 months. Pros: no daily compliance. Cons: requires minor surgical procedure, dose cannot be adjusted between insertions, and pellet extrusion is occasionally reported.

Nasal

Natesto is an FDA-approved intranasal testosterone gel administered three times daily. The short half-life makes it less commonly chosen, but the rapid clearance has theoretical advantages for patients planning future fertility (less suppression of HPG axis).

How to choose a route

The route choice typically comes down to:

  • Lifestyle and adherence. Daily transdermal is easy to forget; weekly injections are easier for some patients to remember.
  • Cost. Generic injectable cypionate is the most cost-effective. Branded oral and transdermal are more expensive.
  • Family considerations. Transdermal carries secondary transfer risk in households with young children or pregnant partners.
  • Fertility plans. Patients planning fertility may prefer routes with less HPG suppression or may use TRT alternatives like enclomiphene.
  • Side effect profile. Some patients tolerate one route better than another based on individual variability.

Monitoring

Standard TRT monitoring across all routes includes:

  • Total testosterone (target mid-normal range).
  • Free testosterone in selected patients.
  • Hematocrit (TRT can produce erythrocytosis).
  • PSA (in patients over 40 or with prostate concerns).
  • Lipid panel.
  • Estradiol (in selected patients with breast tenderness or other estrogen-sensitive symptoms).

Initial monitoring is typically at 3 months and 6 months; annual monitoring afterward in stable patients.

Compounded testosterone

503A compounded testosterone preparations are widely used in U.S. men's health practice. The active pharmaceutical ingredient is the same molecule as branded products. Quality and consistency vary by pharmacy. The same monitoring and clinical considerations apply. Off-label use should be discussed with your clinician.

Risks of TRT

Important risks regardless of route:

  • Erythrocytosis (elevated hematocrit). Regular monitoring required.
  • HPG axis suppression and reduced fertility.
  • Possible cardiovascular effects (the literature has been inconsistent; the TRAVERSE trial published in 2023 found cardiovascular non-inferiority in men with hypogonadism and elevated cardiovascular risk).
  • Possible PSA effects.
  • Acne and oily skin.
  • Sleep apnea worsening in susceptible patients.

A baseline cardiovascular and prostate evaluation is appropriate before TRT initiation.

FAQ

How long until I feel the effects of TRT? Energy and libido changes are often noted within 2-4 weeks. Body composition and muscle changes take 3-6 months. Not all symptoms respond to TRT; thorough evaluation of the contributing causes matters.

Is TRT lifelong? TRT for diagnosed hypogonadism is typically a long-term commitment. Discontinuation generally produces return of symptoms within months.

What about TRT and fertility? TRT suppresses endogenous testosterone and sperm production. For patients planning fertility, alternatives like enclomiphene or HCG-based protocols may be preferable.

Can I switch routes? Yes — switching is reasonable in coordination with a clinician, with appropriate dose conversion and monitoring.

Is "low T" always best treated with TRT? No. Reversible causes (sleep apnea, obesity, medications, hypothyroidism, depression) should be evaluated and addressed first. TRT addresses the symptom but does not always address the underlying cause.

Medical Disclaimer: This content is educational and is not medical advice. Individual results vary. Off-label use should be discussed with your clinician. Compounded medications are prepared by FDA-registered compounding pharmacies but are not FDA-approved as a finished drug product.